Dosage Forms

Articles

The European Medicines Agency’s Committee for Medicinal Products for Human Use has started a rolling review of Vero Cell, an inactivated COVID-19 vaccine developed by Sinovac Life Sciences. 

EMA’s CHMP Starts Rolling Review of Inactivated COVID-19 Vaccine

Moderna has entered into an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of its COVID-19 vaccine to the 92 Gavi COVAX Advance Market Commitment low- and middle-income countries. 

Moderna to Supply Up to 500 Million COVID-19 Vaccine Doses to Low- and Middle-Income Countries

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Complex formulations, personalized medicines, COVID-19 therapies, and sustainability goals are driving innovations in drug packaging.

Injecting Innovation into Drug Packaging

Vaccine development is inherently challenging; however, in light of the COVID-19 pandemic, innovations have been prioritized, leading to accelerated development processes.

Overcoming Vaccine Development Challenges

The European Medicines Agency and the European Centre for Disease Prevention  have joined forces in a new initiative aimed at strengthening the post-marketing surveillance of COVID-19 vaccines in Europe.

EMA, ECDC Team Up to Strengthen Post-Marketing Surveillance of COVID-19 Vaccines

Moderna’s investments will double the formulation fill/finish and drug substance manufacturing of its vaccine to up to three billion doses in 2022 at various manufacturing sites. 

Moderna Announces Additional Investments to Increase COVID-19 Vaccine Supply for 2022

With a $5 million grant from DARPA, DNA Script and Moderna will develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA’s Nucleic Acids On-Demand World-Wide program.

DNA Script to Team up With Moderna for Vaccine and Therapeutic Manufacturing for DARPA

Sanofi will perform the fill/finish of up to 200 million doses of Moderna’s COVID-19 vaccine at its Ridgefield, NJ, facility starting in September 2021. 

Sanofi to Manufacture up to 200 Million Doses of Moderna’s COVID-19 Vaccine

The decision comes from the US CDC Advisory Committee on Immunization Practices following the evaluation of data showing a rare adverse event involving blood clots in combination with low platelet counts within approximately one to two weeks following vaccination.

J&J COVID-19 Vaccinations to Resume in the US

EMA's PRAC has concluded that there is a possible link to rare cases of blood clots with low blood platelets with Janssen’s COVID-19 vaccine.